Ki 67 mib1

Manufactured by Zytomed Systems

Sourced in Germany

The Ki-67/MIB1 is a laboratory equipment product used for the detection and quantification of the Ki-67 protein, a cellular marker associated with cell proliferation. It is a monoclonal antibody-based reagent designed for use in immunohistochemical staining procedures.

Automatically generated - may contain errors

Lab products found in correlation

Melan a, by Agilent Technologies (2 mentions) Hmb45, by Agilent Technologies (1 mentions)

3 protocols using ki 67 mib1

Histopathological Examination of FFPE Tissue

Check if the same lab product or an alternative is used in the 5 most similar protocols

Formalin-fixed paraffin-embedded (FFPE) tissue samples were obtained. For histopathologic examination, 2μm-thin sections were routinely stained with hematoxylin-and-eosin. Additional immunhistochemical stainings for melanocytic marker MelanA (1:100, Dako, Glostrup, Denmark; M7196), the proliferation marker Ki-67/MIB1 (1:200, Zytomed, Berlin, Germany; MSK0810), and p16 (1:200, Zytomed, Berlin, Germany; A4227) were performed. All histologic and IHC sections were reviewed by at least two dermatohistopathologists (EH, KG).

Zaremba A., Jansen P., Murali R., Mayakonda A., Riedel A., Philip M., Rose C., Schaller J., Müller H., Kutzner H., Möller I., Stadtler N., Kretz J., Sucker A., Bankfalvi A., Livingstone E., Zimmer L., Horn S., Paschen A., Plass C., Schadendorf D., Hadaschik E., Lutsik P, & Griewank K. (2022). Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors. International journal of cancer, 151(9), 1542-1554.

+ Open protocol

+ Expand

Histopathological analysis of FFPE samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Formalin-fixed, paraffin-embedded (FFPE) tissue samples were obtained. For histopathologic examination, 2 µm-thin sections were routinely stained with hematoxylin-and-eosin. Additional immunohistochemical staining was performed, including e.g., MelanA (1:100, Dako, Glostrup, Denmark; M7196) and Ki-67/MIB1 (1:200, Zytomed, Berlin, Germany; MSK0810). All histologic and IHC sections were reviewed by at least two board-certified dermatopathologists (EH, KG).

Zaremba A., Jansen P., Murali R., Mayakonda A., Riedel A., Krahl D., Burkhardt H., John S., Géraud C., Philip M., Kretz J., Möller I., Stadtler N., Sucker A., Paschen A., Ugurel S., Zimmer L., Livingstone E., Horn S., Plass C., Schadendorf D., Hadaschik E., Lutsik P, & Griewank K. (2022). Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions. Cancers, 14(17), 4066.

+ Open protocol

+ Expand

Histopathological Characterization of Melanocytic Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Formalin-fixed, paraffin-embedded (FFPE) tissue samples of 19 MT-CNS were
obtained. For histopathologic examination, 2 μm-thin sections were routinely
stained with hematoxylin-and-eosin. Additional immunhistochemical (IHC) stainings for S100
(1:5000, Dako, Glostrup, Danmark; Z0311), melanocytic markers Melan A (1:100, Dako,
Glostrup, Danmark; M7196) and HMB45 (1:200, Dako, Glostrup, Danmark; M0634), BAP1
(described below), and the proliferation marker Ki67/MIB1 (1:200, Zytomed, Berlin,
Germany; MSK0810) were performed.
Diagnoses were made based on criteria described by Brat et al. [23 (link)]. Melanocytomas are well-differentiated
MT-CNS with no or very low mitotic activity (0–1 mitoses per 10 HPF) devoid of CNS
infiltration. Ki67/MIB1-staining is ≤2 %. Intermediate grade melanocytomas
are characterized by increased mitotic activity and microscopic CNS invasion, but are not
sufficiently anaplastic to warrant the designation of malignant melanoma. Ki67/MIB1
staining ranges from 1 to 4 %.
All histologic and IHC sections were reviewed by at least two histopathologists
(JvdN, KGG, MG, TP). The clinico-pathologic details are summarized in Supplemental Table 1.

van de Nes J., Gessi M., Sucker A., Moller I., Stiller M., Horn S., Scholz S.L., Pischler C., Stadtler N., Schilling B., Zimmer L., Hillen U., Scolyer R.A., Buckland M.E., Lauriola L., Pietsch T., Waha A., Schadendorf D., Murali R, & Griewank K.G. (2016). Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. Journal of neuro-oncology, 127(3), 435-444.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!